home / stock / adct / adct quote
Last: | $4.73 |
---|---|
Change Percent: | -0.64% |
Open: | $4.74 |
Close: | $4.73 |
High: | $4.75 |
Low: | $4.4 |
Volume: | 279,091 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.73 | $4.74 | $4.73 | $4.75 | $4.4 | 279,091 | 05-02-2024 |
$4.71 | $4.44 | $4.71 | $4.85 | $4.35 | 398,991 | 05-01-2024 |
$4.41 | $4.47 | $4.41 | $4.58 | $4.35 | 218,872 | 04-30-2024 |
$4.5 | $4.37 | $4.5 | $4.73 | $4.3 | 242,020 | 04-29-2024 |
$4.34 | $4.44 | $4.34 | $4.51 | $4.21 | 323,499 | 04-26-2024 |
$4.44 | $4.65 | $4.44 | $4.65 | $4.41 | 295,796 | 04-25-2024 |
$4.78 | $4.99 | $4.78 | $5 | $4.71 | 276,553 | 04-24-2024 |
$4.97 | $4.72 | $4.97 | $5.08 | $4.72 | 402,955 | 04-23-2024 |
$4.68 | $4.79 | $4.68 | $4.79 | $4.56 | 173,368 | 04-22-2024 |
$4.72 | $4.76 | $4.72 | $4.92 | $4.6 | 646,031 | 04-19-2024 |
$4.76 | $4.95 | $4.76 | $4.95 | $4.72 | 278,551 | 04-18-2024 |
$4.96 | $4.52 | $4.96 | $5.02 | $4.49 | 1,272,321 | 04-17-2024 |
$4.44 | $4.33 | $4.44 | $4.6 | $4.3047 | 238,230 | 04-16-2024 |
$4.37 | $4.39 | $4.37 | $4.47 | $4.11 | 464,878 | 04-15-2024 |
$4.39 | $4.71 | $4.39 | $4.7488 | $4.31 | 337,039 | 04-12-2024 |
$4.68 | $4.77 | $4.68 | $4.86 | $4.52 | 401,625 | 04-11-2024 |
$4.71 | $4.6 | $4.71 | $4.79 | $4.5 | 360,562 | 04-10-2024 |
$4.78 | $5.14 | $4.78 | $5.31 | $4.75 | 446,586 | 04-09-2024 |
$5.09 | $5.02 | $5.09 | $5.38 | $4.93 | 629,623 | 04-08-2024 |
$5 | $4.64 | $5 | $5.1899 | $4.45 | 752,231 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
ADC Therapeutics SA Company Name:
ADCT Stock Symbol:
NYSE Market:
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress again...
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday. Shares of Medifast, Inc. (NYSE:MED) fe...
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been i...